Ultragenyx Reaffirms $730–$760 Million 2026 Revenue Guidance Despite Phase 3 Setback
Ultragenyx reaffirmed 2026 revenue guidance of $730–$760 million despite a Phase 3 clinical failure and a first-quarter net loss, citing its anchored rare disease platform of four approved products and multiple late-stage catalysts expected in H2 2026.
Ultragenyx reaffirmed full-year 2026 revenue guidance of $730–$760 million, maintaining its forecast despite a recent Phase 3 clinical failure and a net loss in the first quarter. The biotech is narrowing its focus to a core rare disease platform anchored by four approved commercial products.
The company is shifting from a broad pipeline strategy to a concentrated portfolio. Management cited cost controls and a scalable commercial base as supports for the unchanged revenue outlook, even as it absorbs the setback from setrusumab and continues to report quarterly losses.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.